← Back to Screener
Silexion Therapeutics Corp Warrant (SLXNW)
Price$0.02
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-71.66%
Price vs S&P 500 (4W)-41.13%
VGM Score15.91
All Metrics
Price vs S&P 500 (YTD)-44.92%
10-Day Avg Trading Volume0.01M
3-Month Avg Trading Volume0.02M
52-Week High$0.15
26-Week Price Return-55.73%
13-Week Price Return-60.85%
3-Month Return Std Dev377.04%
Year-to-Date Return-36.15%
5-Day Price Return0.00%
Month-to-Date Return17.73%
Price vs S&P 500 (13W)-70.60%
Beta-0.92x
52-Week Low$0.01
mGradeF
vgmGradeF
Show chart for
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLXNWSilexion Therapeutics Corp Warrant | — | — | F | $0.02 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing treatments for KRAS-driven cancers. Its lead candidate, SIL204, is a locally administered RNA interference therapy targeting locally advanced pancreatic cancer patients with specific KRAS mutations (G12D/G12V), used in combination with standard chemotherapy. The therapy addresses non-resectable tumors that cannot be surgically removed, representing a significant unmet medical need.